Second-line Therapy With Nal-IRI After Failure Gemcitabine/Nab-paclitaxel in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
Latest Information Update: 22 Apr 2025
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary)
- Indications Adenocarcinoma; Pancreatic ductal carcinoma
- Focus Therapeutic Use
- Acronyms PREDICT
Most Recent Events
- 17 Apr 2025 Status changed from active, no longer recruiting to completed.
- 24 Oct 2023 Results (n=151) demonstrating predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma presented at the 48th European Society for Medical Oncology Congress
- 21 Jan 2023 Results assessing comprehensive evaluation of prior treatment characteristics, potential predictive factors, and quality of life presented at the 2023 Gastrointestinal Cancers Symposium